This site is intended for health professionals only

PREZISTA® oral suspension receives EC approval


Janssen-Cilag International has announced that the European Commission (EC) has approved a 100mg/ml oral suspension of PREZISTA® (darunavir), and the use of darunavir co-administered with low dose ritonavir, for the treatment of human immunodeficiency virus (HIV-1) infection in antiretroviral therapy (ART)-experienced paediatric patients age three years and above, weighing at least 15kg body weight. It must be taken in combination with other ARTs.
To read the rest of this news release and view the MNR, click on the link below:

Most read

Latest Issue

Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine
Share this story: